Sunday 18 October 2026
Export NXL’s income statement to Excel — free account
Nexalin Technology, Inc.
NXL Healthcare Medical Devices
Nexalin Technology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $301,600.00, up 78.8% from fiscal 2024. In the quarter to June 2026, revenue fell 82.7%, EPS fell 10.0% and free cash flow fell 97.2%, each against the same quarter a year earlier.
2.35
0.10
−4.08%
Follow NXL
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | 19.53 | 7.92 | 7.59 | 16.20 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | 96.90 | 41.10 | 134.70 | 116.10 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | 6 | 6 | 6 | 8 | ||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.00 | 0.00 | 0.22 | 0.02 | 0.03 | 0.04 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | 0 | 0 | 0 | 1 | 0 | 0 | 0 | ||||
| Gross margin, % | — | — | — | (5.21) | 88.06 | 85.08 | 72.51 | 76.87 | 78.30 | 79.68 | |||||
| EBT | — | — | — | (5) | (3) | (6) | (2) | (5) | (8) | (8) | |||||
| EBT margin, % | — | — | — | (2,421.02) | (1,401.19) | (4,217.90) | (128.48) | (4,199.37) | (4,512.15) | (2,725.83) | |||||
| Net income | — | — | — | (5) | (3) | (6) | (2) | (5) | (8) | (8) | |||||
| Depreciation | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.03 | 2.04 | 1.02 | 7.12 | 0.45 | 0.55 | 0.55 | ||||
| Earnings | — | — | — | (0.69) | (28.53) | (42.89) | (9.01) | (18.92) | (24.92) | (15.01) | |||||
| Cash flow | — | — | — | (0.09) | (7.24) | (7.60) | (11.94) | (15.65) | (12.85) | (9.08) | |||||
| Capex | — | — | — | 0.00 | 0.00 | 0.00 | (36.61) | (0.49) | (0.55) | (0.18) | |||||
| Free cash flow | — | — | — | (0.09) | (7.24) | (7.60) | (48.55) | (16.14) | (13.41) | (9.26) | |||||
| Book value | — | — | — | (0.16) | (13.33) | (11.87) | 29.52 | 13.09 | 11.98 | 6.87 | |||||
| Shares, m | — | — | — | 7 | 0 | 0 | 0 | 0 | 0 | 1 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | — | 0.00 | 0.00 | 0.00 | 3.31 | 26.43 | 150.63 | 30.30 | |||||
| P/B | — | — | — | 0.00 | 0.00 | 0.00 | 0.80 | 0.91 | 6.91 | 2.44 | |||||
| EV/Sales | — | — | — | 0.00 | 0.00 | 0.00 | (1.98) | (0.16) | 130.03 | 17.97 | |||||
| EV/FCF | — | — | — | (7.58) | (7.58) | (7.58) | 1.18 | 0.00 | (1.99) | (0.45) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (1) | (1) | (1) | (2) | (4) | (4) | (5) | ||||
| Capex | — | — | — | — | 0 | — | (7) | 0 | 0 | 0 | |||||
| Free cash flow | — | — | — | (1) | (1) | (1) | (9) | (4) | (4) | (5) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | (1) | (1) | (2) | 5 | 3 | 3 | 3 | ||||
| Total debt | — | — | — | 1 | 0 | 0 | 0 | — | — | — | |||||
| Net debt | — | — | — | 1 | 0 | (1) | (7) | (3) | (3) | (4) | |||||
| Shareholders’ equity | — | — | — | (1) | (2) | (2) | 5 | 3 | 4 | 4 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | 0.00 | (2,946.75) | (1,393.72) | (41.48) | (84.03) | (193.70) | (185.64) | ||||
| ROIC | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | (1,378.85) | (2,471.51) | (21,146.42) | |||||
| ROE | — | — | — | 0.00 | 245.77 | 371.49 | (89.43) | (107.05) | (221.06) | (221.50) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 2 Oct 2026
Charts ten years each
Nexalin Technology, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| BJDX Bluejay Diagnostics, Inc. | $3.5M | 0.9× | — (loss-making) | — | n/m | +20.05% (above 0%: growing) | 0.00% | 0.00% | Compare |
| ADGM Adagio Medical Holdings, Inc. | $2.8M | — (loss-making) | — | −33.50% (below 0%: shrinking) | n/m | −12.86% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| IVF INVO Fertility, Inc | $2.8M | 0.0× | — (loss-making) | +16.73% (above 0%: growing) | n/m | +35.07% (above 0%: growing) | 35.06% | (59.28%) | Compare |
| NXL Nexalin Technology, Inc. | $2.6M | — (loss-making) | — (loss-making) | −82.72% (below 0%: shrinking) | n/m | −97.23% (below 0%: shrinking) | 72.95% | (18,420.49%) | |
| BIOLQ Biolase, Inc. | $2.3M | — (loss-making) | — (loss-making) | −0.65% (below 0%: shrinking) | n/m | −60.22% (below 0%: shrinking) | 40.39% | (6.41%) | Compare |
| XAIR Beyond Air, Inc. | $2.2M | — (loss-making) | — (loss-making) | +0.45% (above 0%: growing) | n/m | −9.10% (below 0%: shrinking) | 12.73% | (373.98%) | Compare |
| NUVOQ Holdco Nuvo Group D.G Ltd. | $2.1M | — (loss-making) | — | — | n/m | −1.05% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| VJET Flyte Aviation, Inc. | $2.1M | — (loss-making) | — (loss-making) | +380.66% (above 0%: growing) | n/m | −26.70% (below 0%: shrinking) | 9.62% | (388.13%) | Compare |
| NUWE Nuwellis, Inc. | $2.0M | — (loss-making) | — (loss-making) | +14.14% (above 0%: growing) | n/m | −51.55% (below 0%: shrinking) | 76.08% | (160.94%) | Compare |
| Median of peers | $2.3M | — | — | +7.30% | — | −10.98% | 11.17% | (32.84%) |
Nexalin Technology, Inc. (NXL) key facts
- Strength: Nexalin Technology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $301,600.00, up 78.8% from fiscal 2024.
- Nexalin Technology, Inc. (NXL) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, NXL traded at $2.35, a market capitalization of $2.6 million.
- Return on equity was −221.5% and debt-to-equity 0.00.
- Its Piotroski F-score is 5 out of 9 and its Altman Z-score is −26.89 (distress zone) for fiscal 2025.